These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy.
    Author: Annaberdyev S, Gibbons J, Hardacre JM.
    Journal: World J Surg Oncol; 2009 Mar 16; 7():30. PubMed ID: 19291285.
    Abstract:
    Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.
    [Abstract] [Full Text] [Related] [New Search]